Close

AVI BioPharma starts patient dosing in DMG drug Phase 2 trial

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Biopharma Production with AI: A New Era in Manufacturing

A New Era of Biopharma Production with AI The biopharma...

AI Drug Discovery Transforming APAC Biopharma Innovation

The Asia-Pacific (APAC) biopharmaceutical space is being revolutionized by...

Projected Growth of Injectable Drug Market To $1139B By 2029

According to a recent analysis released by MarketsandMarkets, the...

AVI BioPharma has started patient dosing in a placebo-controlled Phase 2 trial to evaluate eteplirsen as a treatment for Duchenne muscular dystrophy (DMD).The study intends to investigate the safety and efficacy of eteplirsen in DMD patients over 24 weeks of dosing. In the trial, the patients will be given once weekly intravenous infusions of either 50mg/kg of eteplirsen, 30mg/kg of eteplirsen or placebo, and will be evaluated on a number of safety and efficacy endpoints.

AVI president and CEO Chris Garabedian said in this Phase 2 study they will evaluate eteplirsen at higher doses and over a longer duration of treatment, which will help them understand the potential disease-modifying effects and safety of eteplirsen as chronically-administered therapy.”We expect data from this study around the end of the second quarter of 2012, which will guide our design for a pivotal study,” Garabedian said.

Latest stories

Related stories

Biopharma Production with AI: A New Era in Manufacturing

A New Era of Biopharma Production with AI The biopharma...

AI Drug Discovery Transforming APAC Biopharma Innovation

The Asia-Pacific (APAC) biopharmaceutical space is being revolutionized by...

Projected Growth of Injectable Drug Market To $1139B By 2029

According to a recent analysis released by MarketsandMarkets, the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back